137 related articles for article (PubMed ID: 25892855)
1. The expression of TLR-9, CD86, and CD95 phenotypes in circulating B cells of patients with chronic viral hepatitis B or C before and after antiviral therapy.
Zhao PW; Ma L; Ji HF; Yu L; Feng JY; Wang J; Liu MY; Jiang YF
Mediators Inflamm; 2015; 2015():762709. PubMed ID: 25892855
[TBL] [Abstract][Full Text] [Related]
2. Antiviral treatment improves disrupted peripheral B lymphocyte homeostasis in chronic hepatitis B virus-infected patients.
Sun H; Lv J; Tu Z; Hu X; Yan H; Pan Y; Xu D; Lian Z; Chi X; Niu J
Exp Biol Med (Maywood); 2013 Nov; 238(11):1275-83. PubMed ID: 24085784
[TBL] [Abstract][Full Text] [Related]
3. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
5. Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
Zhang L; Wang Q; Zhao P; Hu X; Jiang Y
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):514-23. PubMed ID: 24773272
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
Zhao H; Li J; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL; Si CW
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):282-4. PubMed ID: 17971947
[TBL] [Abstract][Full Text] [Related]
7. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
8. HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.
Tseng KC; Cheng PN; Wu IC; Chang CK; Chou AL; Liu WC; Chang TT
Hepatogastroenterology; 2009; 56(91-92):813-8. PubMed ID: 19621708
[TBL] [Abstract][Full Text] [Related]
9. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
11. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
12. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
13. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
14. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
[TBL] [Abstract][Full Text] [Related]
15. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
[TBL] [Abstract][Full Text] [Related]
16. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
17. [TLR9 expression is positively correlated with the levels of CD38, HLA-DR and CD95 on peripheral blood mononuclear cells in chronic HBV infected patients].
Mao X; Peng L; Liu X; Yang Y; Wang Q; Wang D; Xiao J; Leng J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):660-5. PubMed ID: 27126946
[TBL] [Abstract][Full Text] [Related]
18. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
19. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
20. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
